[go: up one dir, main page]

GB201815775D0 - Chimeric antigen receptor - Google Patents

Chimeric antigen receptor

Info

Publication number
GB201815775D0
GB201815775D0 GBGB1815775.0A GB201815775A GB201815775D0 GB 201815775 D0 GB201815775 D0 GB 201815775D0 GB 201815775 A GB201815775 A GB 201815775A GB 201815775 D0 GB201815775 D0 GB 201815775D0
Authority
GB
United Kingdom
Prior art keywords
antigen receptor
chimeric antigen
chimeric
receptor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1815775.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Priority to GBGB1815775.0A priority Critical patent/GB201815775D0/en
Publication of GB201815775D0 publication Critical patent/GB201815775D0/en
Priority to HUE19779542A priority patent/HUE069503T2/en
Priority to CA3113896A priority patent/CA3113896A1/en
Priority to CN201980063392.7A priority patent/CN112771076B/en
Priority to BR112021004986-0A priority patent/BR112021004986B1/en
Priority to PCT/GB2019/052726 priority patent/WO2020065330A2/en
Priority to NZ773507A priority patent/NZ773507A/en
Priority to DK19779542.0T priority patent/DK3856775T3/en
Priority to PT197795420T priority patent/PT3856775T/en
Priority to CN202410407389.5A priority patent/CN118459606A/en
Priority to FIEP19779542.0T priority patent/FI3856775T3/en
Priority to AU2019348975A priority patent/AU2019348975B2/en
Priority to EP19779542.0A priority patent/EP3856775B9/en
Priority to JP2021516889A priority patent/JP7458382B2/en
Priority to MX2021003636A priority patent/MX2021003636A/en
Priority to SG11202102781UA priority patent/SG11202102781UA/en
Priority to KR1020217012340A priority patent/KR20210066865A/en
Priority to IL281428A priority patent/IL281428B2/en
Priority to ES19779542T priority patent/ES3012752T3/en
Priority to PL19779542.0T priority patent/PL3856775T3/en
Priority to US17/279,874 priority patent/US12049510B2/en
Priority to ZA2021/01495A priority patent/ZA202101495B/en
Priority to CL2021000736A priority patent/CL2021000736A1/en
Priority to US17/746,642 priority patent/US12454578B2/en
Priority to JP2023162990A priority patent/JP7594067B2/en
Priority to JP2024162093A priority patent/JP2024178295A/en
Priority to US18/978,527 priority patent/US20250277047A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
GBGB1815775.0A 2018-09-27 2018-09-27 Chimeric antigen receptor Ceased GB201815775D0 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GBGB1815775.0A GB201815775D0 (en) 2018-09-27 2018-09-27 Chimeric antigen receptor
US17/279,874 US12049510B2 (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
EP19779542.0A EP3856775B9 (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
MX2021003636A MX2021003636A (en) 2018-09-27 2019-09-26 CHIMERIC ANTIGEN RECEPTOR.
CN201980063392.7A CN112771076B (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
BR112021004986-0A BR112021004986B1 (en) 2018-09-27 2019-09-26 CHIMERIC ANTIGEN RECEPTOR
PCT/GB2019/052726 WO2020065330A2 (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
NZ773507A NZ773507A (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
DK19779542.0T DK3856775T3 (en) 2018-09-27 2019-09-26 CHIMERIC ANTIGEN RECEPTOR
PT197795420T PT3856775T (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
CN202410407389.5A CN118459606A (en) 2018-09-27 2019-09-26 Chimeric Antigen Receptor
FIEP19779542.0T FI3856775T3 (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
AU2019348975A AU2019348975B2 (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
HUE19779542A HUE069503T2 (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
JP2021516889A JP7458382B2 (en) 2018-09-27 2019-09-26 Chimeric Antigen Receptor
CA3113896A CA3113896A1 (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
SG11202102781UA SG11202102781UA (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
KR1020217012340A KR20210066865A (en) 2018-09-27 2019-09-26 Chimeric Antigen Receptor
IL281428A IL281428B2 (en) 2018-09-27 2019-09-26 chimeric antigen receptor
ES19779542T ES3012752T3 (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
PL19779542.0T PL3856775T3 (en) 2018-09-27 2019-09-26 Chimeric antigen receptor
ZA2021/01495A ZA202101495B (en) 2018-09-27 2021-03-04 Chimeric antigen receptor
CL2021000736A CL2021000736A1 (en) 2018-09-27 2021-03-24 Chimeric antigen receptor.
US17/746,642 US12454578B2 (en) 2018-09-27 2022-05-17 Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors
JP2023162990A JP7594067B2 (en) 2018-09-27 2023-09-26 Chimeric Antigen Receptor
JP2024162093A JP2024178295A (en) 2018-09-27 2024-09-19 Chimeric Antigen Receptor
US18/978,527 US20250277047A1 (en) 2018-09-27 2024-12-12 Chimeric antigen receptor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1815775.0A GB201815775D0 (en) 2018-09-27 2018-09-27 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
GB201815775D0 true GB201815775D0 (en) 2018-11-14

Family

ID=64108945

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1815775.0A Ceased GB201815775D0 (en) 2018-09-27 2018-09-27 Chimeric antigen receptor

Country Status (1)

Country Link
GB (1) GB201815775D0 (en)

Similar Documents

Publication Publication Date Title
SG11202102781UA (en) Chimeric antigen receptor
IL276396B2 (en) Chimeric antigen receptors targeting cd70
IL254254B (en) Chimeric antigen receptor
GB201607968D0 (en) Chimeric antigen receptor
GB201807870D0 (en) A CD79-specific chimeric antigen receptor
GB201610512D0 (en) Chimeric antigen receptor
GB201503742D0 (en) Chimeric antigen receptor
ZA201906321B (en) Chimeric antigen receptor
ZA202005837B (en) Cd83-binding chimeric antigen receptors
IL277946A (en) Chimeric antigen receptor specific for interleukin-23 receptor
IL289899A (en) Anti-hk2 chimeric antigen receptor
GB201709508D0 (en) Chimeric antigen receptor
GB201801831D0 (en) Chimeric receptor
IL278992A (en) Chimeric antigen receptor t cell therapy
GB201807862D0 (en) Chimeric antigen receptor
GB201519900D0 (en) Chimeric antigen receptor
GB201721421D0 (en) Chimeric antigen receptor
GB201815775D0 (en) Chimeric antigen receptor
GB201809773D0 (en) Chimeric antigen receptor
GB201807866D0 (en) Chimeric antigen receptor
GB201906406D0 (en) Chimeric antigen receptor
GB201902021D0 (en) Chimeric antigen receptor
HK40038585A (en) Chimeric antigen receptor
GB201908239D0 (en) Chimeric antigen receptors
HK40043730A (en) Cd83-binding chimeric antigen receptors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)